BRPI0822239A2 - Composto de pirazolo[1,5-a] pirimidina - Google Patents
Composto de pirazolo[1,5-a] pirimidinaInfo
- Publication number
- BRPI0822239A2 BRPI0822239A2 BRPI0822239-8A BRPI0822239A BRPI0822239A2 BR PI0822239 A2 BRPI0822239 A2 BR PI0822239A2 BR PI0822239 A BRPI0822239 A BR PI0822239A BR PI0822239 A2 BRPI0822239 A2 BR PI0822239A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazolo
- pyrimidine compound
- pyrimidine
- compound
- Prior art date
Links
- -1 Pyrazolo [1,5-a] pyrimidine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1586207P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/087717 WO2009086129A1 (en) | 2007-12-21 | 2008-12-19 | Pyrazolo [1,5-a] pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0822239A2 true BRPI0822239A2 (pt) | 2015-06-30 |
Family
ID=40456929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0822239-8A BRPI0822239A2 (pt) | 2007-12-21 | 2008-12-19 | Composto de pirazolo[1,5-a] pirimidina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100324073A1 (pt) |
| EP (1) | EP2235020A1 (pt) |
| JP (1) | JP2011507901A (pt) |
| CN (1) | CN101952293A (pt) |
| AU (1) | AU2008345687A1 (pt) |
| BR (1) | BRPI0822239A2 (pt) |
| CA (1) | CA2710454A1 (pt) |
| WO (1) | WO2009086129A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2526675T3 (es) | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| SG11201405328SA (en) | 2012-03-16 | 2014-11-27 | Vitae Pharmaceuticals Inc | Liver x receptor modulators |
| ES2607113T3 (es) | 2012-03-16 | 2017-03-29 | Vitae Pharmaceuticals, Inc. | Moduladores de los receptores X del hígado |
| WO2014028461A2 (en) | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
| AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| EP3129376B1 (en) | 2014-03-27 | 2018-12-26 | Janssen Pharmaceutica NV | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors |
| US10342795B2 (en) | 2014-03-27 | 2019-07-09 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors |
| AU2017207291B2 (en) | 2016-01-11 | 2023-06-15 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ，インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354675A1 (en) * | 1999-09-30 | 2004-02-09 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| US20040259948A1 (en) * | 2003-01-10 | 2004-12-23 | Peter Tontonoz | Reciprocal regulation of inflammation and lipid metabolism by liver X receptors |
| GT200500208A (es) * | 2004-08-03 | 2006-03-02 | Indazoles ùtiles para tratar enfermedades cardiovasculares | |
| RU2007131400A (ru) * | 2005-03-01 | 2009-04-10 | Вайет (Us) | Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени |
| ATE463495T1 (de) * | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| US20080070883A1 (en) * | 2006-09-19 | 2008-03-20 | Wyeth | Use of LXR modulators for the prevention and treatment of skin aging |
-
2008
- 2008-12-19 EP EP08867591A patent/EP2235020A1/en not_active Withdrawn
- 2008-12-19 WO PCT/US2008/087717 patent/WO2009086129A1/en not_active Ceased
- 2008-12-19 US US12/809,851 patent/US20100324073A1/en not_active Abandoned
- 2008-12-19 AU AU2008345687A patent/AU2008345687A1/en not_active Abandoned
- 2008-12-19 CA CA2710454A patent/CA2710454A1/en not_active Abandoned
- 2008-12-19 JP JP2010539880A patent/JP2011507901A/ja not_active Withdrawn
- 2008-12-19 CN CN2008801273723A patent/CN101952293A/zh active Pending
- 2008-12-19 BR BRPI0822239-8A patent/BRPI0822239A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2235020A1 (en) | 2010-10-06 |
| WO2009086129A1 (en) | 2009-07-09 |
| CN101952293A (zh) | 2011-01-19 |
| AU2008345687A1 (en) | 2009-07-09 |
| CA2710454A1 (en) | 2009-07-09 |
| US20100324073A1 (en) | 2010-12-23 |
| JP2011507901A (ja) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024030I2 (el) | Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β | |
| DK2384326T3 (da) | Pyrrolo[2,3-d]pyrimidinforbindelser | |
| LTPA2020504I1 (lt) | Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai | |
| BRPI0822237A2 (pt) | Compostos de imidazo [1,2-a] piridina | |
| ZA201004368B (en) | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors | |
| DK1797099T3 (da) | Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser | |
| IL195238A0 (en) | Pyrazolo [1,5-a]pyrimidines as cdk inhibitors | |
| ZA201202718B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| SI1904494T1 (sl) | Imidazo(1,2-a)piridin spojine kot inhibitorji vegf-r2 | |
| ZA200805294B (en) | Pyrimidine derivatives | |
| PT3184526T (pt) | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus | |
| ZA201004823B (en) | Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents | |
| DK2137184T3 (da) | Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer | |
| BRPI0819831A2 (pt) | derivados de amidas de áciodo 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-carboxílico | |
| GB0525080D0 (en) | Pyrimidine derivatives | |
| GB0525083D0 (en) | Pyrimidine derivatives | |
| EP2323663A4 (en) | 4-amino-3- (imidazolyl) -PYRAZOLO- [3,4-D] pyrimidines | |
| DK2167470T3 (da) | Triazolo-[1,5A]-chinoliner som adenosin-A3-receptor ligander | |
| ZA200804335B (en) | Substituted bicyclic pyrimidone derivatives | |
| GB0525081D0 (en) | Pyrimidine derivatives | |
| EP2511276A4 (en) | Pyrrolo [2,3-D] pyrimidine derivative | |
| AP2008004437A0 (en) | Pyrazolo Ä4,3-DÜ pyrimidin-5-yl) derivative used as PDE5 inhibitors | |
| DK2059521T3 (da) | Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger | |
| TWI372760B (en) | A pyrazolo[1,5-a]pyrimidine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |